Belsomra Withdrawal & Tapering Guide
suvorexant
In short
Belsomra (suvorexant) is an Other with a half-life of ~12 hours. Most patients can step down with a 1-2 week taper given the lower dependence liability. Withdrawal symptoms, when they occur, usually begin 1-3 days and settle within 1-2 weeks for most.
- Class
- Other
- Half-life
- ~12 hours
- Common doses
- 5mg, 10mg, 15mg, 20mg tablets
- Withdrawal onset
- 1-3 days
- Typical resolution
- 1-2 weeks for most
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Suvorexant is a dual orexin receptor antagonist (DORA) — it works by blocking the wakefulness-promoting orexin system rather than enhancing GABA. Less risk of dependence compared with benzos and Z-drugs, but next-day sedation and sleep paralysis are common.
5mg, 10mg, 15mg, 20mg tablets
Tablets: 5mg, 10mg, 15mg, 20mg
Category C
Mechanism of Action
Dual antagonist at orexin OX1 and OX2 receptors, suppressing the wake-promoting orexin/hypocretin signal.
Taper Notes
Most patients can step down with a 1-2 week taper given the lower dependence liability.
Hyperbolic Tapering Guidance
Among the easier hypnotics to discontinue. Still worth a planned step-down rather than abrupt cessation if used nightly for months.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
1-3 days
3-7 days
1-2 weeks for most
Rarely reported beyond 4 weeks
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Strong CYP3A4 inhibitors — contraindicated or dose reduction
- CNS depressants — additive sedation
Contraindications
- Narcolepsy
Toxicity
Next-day somnolence, sleep paralysis, hypnagogic hallucinations, complex sleep behaviors (less common than Z-drugs but reported).
Pharmacokinetics
ADME Profile
Hepatic via CYP3A4 (major).
~99%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Frequently asked questions about Belsomra
What are the withdrawal symptoms of Belsomra (suvorexant)?
Common withdrawal symptoms of Belsomra (suvorexant) include: rebound insomnia (mild), occasional vivid dreams. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Belsomra (suvorexant)?
Most patients can step down with a 1-2 week taper given the lower dependence liability. Among the easier hypnotics to discontinue. Still worth a planned step-down rather than abrupt cessation if used nightly for months.
How long does Belsomra withdrawal last?
Belsomra withdrawal typically begins 1-3 days, peaks around 3-7 days, and resolves within 1-2 weeks for most. Rarely reported beyond 4 weeks
Can I stop Belsomra cold turkey?
Stopping Belsomra abruptly is not recommended. Its half-life is ~12 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Belsomra stay in your system?
Belsomra (suvorexant) has a half-life of ~12 hours. A drug is mostly cleared after about five half-lives, so Belsomra is largely out of the body about 3 days after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Belsomra (suvorexant) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — benzodiazepine receptor agonist algorithm — Evidence-based Z-drug / BZRA deprescribing algorithm
- British National Formulary (BNF) — UK formulary guidance on hypnotic prescribing
- Cochrane Library — Z-drug reviews — Systematic reviews of hypnotic efficacy and safety
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- BenzoBuddies — Z-drug section — Peer-support community covering Z-drug tapering
- Benzodiazepine Information Coalition — Education on benzodiazepine-receptor-agonist dependence
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- Mad in America — sleep medication archive — Journalism on hypnotic prescribing and withdrawal
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.